Literature DB >> 866579

Clinical and biochemical studies in Engelmann's disease (progressive diaphyseal dysplasia).

R Smith, R J Walton, B D Corner, I R Gordon.   

Abstract

The clinical and biochemical features of four adults with Engelmann's disease (Camurati-Engelmann disease; progressive diaphyseal dysplasia) are presented. One young patient, with a particularly severe form of the disease, is discussed in detail. Biochemical abnormalities were found in three of the patients. In two of them, one with localized hyperostosis and one with generalized bone disease, the only changes were an increase in the plasma alkaline phosphatase and urinary total hydroxyproline excretion. The most severely affected patients, who had had progressive and generalized bone disease from age two and a half years, also had persistent hypocalcaemia and hyperphosphataemia, a positive calcium balance, and a very low urine calcium excretion. It is suggested that some patients with Engelmann's disease may have a previously unrecognized metabolic disorder associated with increased retention of calcium and excessive bone formation. The possible role of abnormal phosphate metabolism in this increased formation of bone, and the relationship of Engelmann's disease to other hyperostoses, are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 866579

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  13 in total

1.  Genetic mapping of the Camurati-Engelmann disease locus to chromosome 19q13.1-q13.3.

Authors:  M Ghadami; Y Makita; K Yoshida; G Nishimura; Y Fukushima; K Wakui; S Ikegawa; K Yamada; S Kondo; N Niikawa; H a Tomita
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Camurati-Engelmann disease: failure of response to bisphosphonates: report of two cases.

Authors:  Glaucio R W Castro; Simone Appenzeller; João Francisco Marques-Neto; Manoel B Bértolo; Adil M Samara; Ibsen Coimbra
Journal:  Clin Rheumatol       Date:  2005-01-20       Impact factor: 2.980

3.  Papilloedema, a complication of progressive diaphyseal dysplasia: a series of three case reports.

Authors:  M Wright; N R Miller; R M McFadzean; P Riordan-Eva; A G Lee; M D Sanders; G G McIlwaine
Journal:  Br J Ophthalmol       Date:  1998-09       Impact factor: 4.638

4.  Discrepancy between bone density and bone material strength index in three siblings with Camurati-Engelmann disease.

Authors:  S Herrera; R Soriano; X Nogués; R Güerri-Fernandez; D Grinberg; N García-Giralt; N Martínez-Gil; S Castejón; A González-Lizarán; S Balcells; A Diez-Perez
Journal:  Osteoporos Int       Date:  2017-08-25       Impact factor: 4.507

5.  Fatal cerebellar herniation secondary to Camurati-Englemann's disease.

Authors:  R K Simpson; D K Fischer; G K Gall; J E Rose
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

Review 6.  Craniotubular bone disorders.

Authors:  R J Gorlin
Journal:  Pediatr Radiol       Date:  1994

Review 7.  Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment.

Authors:  K Janssens; F Vanhoenacker; M Bonduelle; L Verbruggen; L Van Maldergem; S Ralston; N Guañabens; N Migone; S Wientroub; M T Divizia; C Bergmann; C Bennett; S Simsek; S Melançon; T Cundy; W Van Hul
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

8.  Case report 202. Engelmann disease of bone (diaphyseal dysplasia) with bilateral shortened fibulae.

Authors:  A J Crisp; D P Brenton; D G Shaw
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

9.  Engelmann's disease of bone--a systemic disorder?

Authors:  A J Crisp; D P Brenton
Journal:  Ann Rheum Dis       Date:  1982-04       Impact factor: 19.103

Review 10.  Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management.

Authors:  Celia L Gregson; Sarah A Hardcastle; Cyrus Cooper; Jonathan H Tobias
Journal:  Rheumatology (Oxford)       Date:  2013-02-27       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.